Literature DB >> 21329776

Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression.

Torsak Bunupuradah1, Jintanat Ananworanich, Chitsanu Pancharoen, Kathy Petoumenos, Wasana Prasitsuebsai, Walaiporn Wongngam, Sasiwimol Ubolyam, Chulalak Sriheara, Joep Lange, Praphan Phanuphak, Thanyawee Puthanakit.   

Abstract

HIV infected individuals have poorer response to hepatitis B vaccine (HBV) compared to normal host. Intradermal administration (i.d.) facilitates the exposure of antigen to antigen-presenting cells compared to intramuscular administration (i.m.). HIV-infected children aged 1-18 years with CD4%≥15% or 200 cells/mm(3) who had negative HBs Ag, antiHBs, and antiHBc were randomized to receive 3-dose of HBV via i.d. (2 μg/dose) or i.m. (10 μg/dose) route at months 0, 2, and 6. AntiHBs titers were measured at months 2, 6 and 7 after first HBV. AntiHBs≥10 mIU/mL was considered protective and AntiHBs>100 mIU/mL was considered good response. Participants included 41 in i.d. and 39 in i.m. arms. 64% had completed 3-doses HBV during infancy. The mean (SD) of age, nadir CD4% and current CD4% were 12 (3.3) years, 10.6 (7.9)% and 28 (8.0)% respectively. 91% were on HAART and 84% had undetectable HIV-RNA. Proportion of children with protective antiHBs in i.d. vs. i.m. group were 19.5% vs. 25.6% at month 2, 56.1% vs. 76.9% at month 6, and 90.2% vs. 92.3% at month 7 (NS, all). The geometric mean (95% confidence interval) of antiHBs titer in i.d. vs. i.m. group were 112.5 (34.4-367.6) vs. 141.2 (49.4-404.1) mIU/mL at month 2 (p=0.74), 70.4 (39.8-124.4) vs. 132.1 (79.4-219.8) mIU/mL at month 6 (p=0.10), and 157.0 (103.0-239.3) vs. 458.9 (324.0-647.0) mIU/mL at month 7 (p<0.001). However, only 56.1% of the i.d. arm had good response to HBV compared to 82.1% in the i.m. arm (p=0.01). The predictors for being a good responder to HBV were i.m. administration [OR 4.0, 95%CI 1.4-11.8, p=0.012] and body weight <35 kg at baseline [OR 3.8, 95%CI 1.3-10.8, p=0.013]. No adverse events grade 3/4 occurred. In conclusion, HIV-infected children without severe immune suppression, both i.d. and i.m. routes of HBV resulted in similar rates of protective antibody titers. However, high antibody titers to HBV were more common with i.m.; therefore, i.m. administration is preferred.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21329776     DOI: 10.1016/j.vaccine.2011.01.114

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

2.  Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database.

Authors:  Linda Aurpibul; Azar Kariminia; Ung Vibol; Moy Siew Fong; Oanh Ngoc Le; Rawiwan Hansudewechakul; Torsak Bunupuradah; Nia Kurniati; Kulkanya Chokephaibulkit; Nagalingeswaran Kumarasamy; Dewi Kumara Wati; Nik Khairulddin Nik Yusoff; Kamarul Azahar Mohd Razali; Revathy A Nallusamy; Annette H Sohn; Pagakrong Lumbiganon
Journal:  Pediatr Infect Dis J       Date:  2018-08       Impact factor: 2.129

Review 3.  Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV.

Authors:  Priya D Farooq; Kenneth E Sherman
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.071

Review 4.  Hepatitis B vaccine by intradermal route in non responder patients: an update.

Authors:  Martina Filippelli; Elena Lionetti; Alessia Gennaro; Angela Lanzafame; Teresa Arrigo; Carmelo Salpietro; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children.

Authors:  Salvatore Leonardi; Andrea Domenico Praticò; Elena Lionetti; Massimo Spina; Giovanna Vitaliti; Mario La Rosa
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

Review 6.  Intradermal vaccination for infants and children.

Authors:  Akihiko Saitoh; Yuta Aizawa
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

Review 7.  Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection.

Authors:  Mbah P Okwen; Savanna Reid; Basile Njei; Lawrence Mbuagbaw
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09

8.  Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination.

Authors:  Amitis Ramezani; Alireza Janbakhsh; Maryam Gol-Mohammadi; Mohammad Banifazl; Arezoo Aghakhani; Ali Eslamifar; Zahra Pournasiri; Behzad Mahdavian; Ali-Asghar Farazi; Masoomeh Sofian
Journal:  Perspect Clin Res       Date:  2014-07

Review 9.  Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis.

Authors:  Jenny L Schnyder; Cornelis A De Pijper; Hannah M Garcia Garrido; Joost G Daams; Abraham Goorhuis; Cornelis Stijnis; Frieder Schaumburg; Martin P Grobusch
Journal:  Travel Med Infect Dis       Date:  2020-09-06       Impact factor: 6.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.